


**PRODUCT: GSK1904529A**

**ALTERNATE NAME:** N-(2,6-difluorophenyl)-5-(3-(2-(5-ethyl-2-methoxy-4-(4-(4-(methylsulfonyl)piperazin-1-yl)piperidin-1-yl)phenylamino)pyrimidin-4-yl)H-imidazo[1,2-a]pyridin-2-yl)-2-methoxybenzamide

**CATALOG #:** 2286-5, 25

**AMOUNT:** 5 mg, 25 mg

**STRUCTURE:**



**MOLECULAR FORMULA:** C<sub>44</sub>H<sub>47</sub>F<sub>2</sub>N<sub>9</sub>O<sub>5</sub>S

**MOLECULAR WEIGHT:** 851.96

**CAS NUMBER:** 1089283-49-7

**APPEARANCE:** Crystalline solid

**SOLUBILITY:** DMSO (>100 mg/ml)

**PURITY:** ≥98% by HPLC

**STORAGE:** At -20° C. Protect from light and moisture

**DESCRIPTION:** A potent, selective, reversible and ATP-competitive inhibitor of the insulin-like growth factor-1 receptor (IGF-1R) and Insulin Receptor (IR) with IC<sub>50</sub>s of 27 and 25 nM, respectively.

**REFERENCE:** Sabbatini, P., *et al.* (2009). *Clin. Cancer Res.* **15**, 3058-3067.

**HANDLING:** Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.

**RELATED PRODUCTS:**

- ABT-869 (Cat. No. 1615-1, 5)
- Angiostatin, Human (Cat. No. 4919-100, 500)
- Angiostatin, K1-3, Human (Cat. No. 4920-20, 100, 500)
- BAY 43-9006 (Cat. No. 1594-25, 100)
- BAY 43-9006, Free base (Cat. No. 2142-25, 100)
- EZSolution™ BAY 43-9006 (Cat. No. 2031-25)
- BIBF1120 (Cat. No. 2167-5, 25)
- Carbozantinib (Cat. No. 1935-5, 25)
- Cediranib (Cat. No. 1613-1, 5)
- Endostatin, human recombinant (Cat. No. 4759-20, 100,100)
- GW-786034 (Cat. No. 1916-5, 25)
- Motesanib (Cat. No. 2022-5, 25)
- SU 1498 (Cat. No. 1836-1, 5)
- SU 6 Thiabendazole (Cat. No. 2161-1G)
- Tranilast (Cat. No. 1876-10, 50)
- 668 (Cat. No. 1931-5, 25)
- Vandetanib (Cat. No. 1751-25, 100)
- Vatalanib, dihydrochloride (Cat. No. 2025-5, 25)
- Vatalanib, Free base (Cat. No. 2026-5, 25)

**USAGE:** *FOR RESEARCH CH USE ONLY! Not to be used in humans*